Investigators from Shanghai, China, report responses above 90% by using levantinib and tislelizumab to treat patients with a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback